Cannabidiol and epilepsy

Int Rev Neurobiol. 2024:177:135-147. doi: 10.1016/bs.irn.2024.03.009. Epub 2024 Apr 6.

Abstract

Cannabidiol (CBD) has been investigated as a pharmacological approach for treating a myriad of neurological and psychiatric disorders, the most successful of them being its use as an antiseizure drug (ASD). Indeed, CBD has reached the clinics for the treatment of certain epileptic syndromes. This chapter aims to overview the pharmacology of CBD and its potential mechanisms of action as an ASD. First, we give an outline of the concepts, mechanisms and pharmacology pertaining to the field of study of epilepsy and epileptic seizures. In the second section, we will summarize the effects of CBD as an ASD. Next, we will discuss its potential mechanisms of action to alleviate epileptic seizures, which seem to entail multiple neurotransmitters, receptors and intracellular pathways. Finally, we will conclude and present some limitations and perspectives for future studies.

Keywords: Antiseizure drugs; Cannabidiol; Cannabinoids; Epilepsy; Seizure.

Publication types

  • Review

MeSH terms

  • Animals
  • Anticonvulsants* / pharmacology
  • Anticonvulsants* / therapeutic use
  • Cannabidiol* / pharmacology
  • Cannabidiol* / therapeutic use
  • Epilepsy* / drug therapy
  • Humans

Substances

  • Cannabidiol
  • Anticonvulsants